Abstract Submission Period
Abstracts for oral, poster or video presentation
| From Friday, July 28 to Friday, September 15, 2017 | |
| Final deadline has been extended to Noon, | September 22, 2017 (JST). September 29, 2017 (JST). October 2, 2017 (JST). |
Presentation Style
Please select one of the presentation styles below:
- Oral presentation
- Poster presentation (Time for oral presentation available)
Video presentation
* The detailed information for preparation of the presentation slides and data will be announced after the notification of the acceptance or rejection.
Presentation Categories
Please select the most appropriate category for your presentation.
The Program Committee will make the final decision on the presentation categories.
Symposium / Panel discussion / Workshop / Video Workshop categories
Purpose of application for each session Please refer to the program page for details.
Symposium
- Conversion surgery for advanced gastric cancer: controversy and perspectives.
【English】
Panel discussion
- Treatment of esophagogastric junction cancer: future direction
【English】 - Indication of laparoscopic gastretomy for advanced gastric cancer: current status and future prospects
【English】
Workshop
- Treatment of elderly gastric cancer patients
【English】 - Treatment for the gastric cancer patients with peritoneal dissemination.
【English】
Video Workshop
- Tips and pitfalls in endoscopic surgery for esophagogastric junction cancer
【English】 - Reconstruction after laparoscopic total gastrectomy
【English】
Oral / Video / Poster Categories
| 1 | Epidemiology |
|---|---|
| 2 | Pathology |
| 3 | Molecular biology |
| 4 | Molecular pathology |
| 5 | Genomics |
| 6 | Epigenomics |
| 7 | Development of gastric cancer |
| 8 | Translational research |
| 9 | H.pylori |
| 10 | Progression of gastric cancer |
| 11 | Micrometastasis |
| 12 | Intraoperative frozen section |
| 13 | Cancer stem cell |
| 14 | Gastric cancer screening |
| 15 | Endoscopic diagnosis |
| 16 | IEE |
| 17 | Endoscopic resection |
| 18 | Imaging diagnosis |
| 19 | Clinical study |
| 20 | Chemotherapy |
| 21 | Neoadjuvant chemotherapy |
| 22 | Adjuvant chemotherapy |
| 23 | Second-line chemotherapy |
| 24 | Intraperitoneal chemotherapy |
| 25 | Molecular targeted therapy |
| 26 | Biomarker |
| 27 | Immunotherapy |
| 28 | Radiation therapy |
| 29 | Chemoradiotherapy |
| 30 | Conversion surgery |
| 31 | Surgery |
| 32 | Laparoscopic surgery |
| 33 | Function-preserving surgery |
| 34 | Cytoreductive surgery |
| 35 | LECS |
| 36 | Surgical navigation |
| 37 | Postoperative functional assessment |
| 38 | Postgastrectomy syndrome |
| 39 | Perioperative management |
| 40 | Postoperative complications |
| 41 | ERAS |
|---|---|
| 42 | Sentinel lymph node |
| 43 | Peritoneal dissemination |
| 44 | CART |
| 45 | Stent placement |
| 46 | Liver metastasis |
| 47 | Recurrence |
| 48 | Early gastric cancer |
| 49 | Advanced gastric cancer |
| 50 | Scirrhous gastric cancer |
| 51 | Gastric stump carcinoma |
| 52 | Multiple gastric cancers |
| 53 | Gastric tube cancer |
| 54 | Gastric cardia cancer |
| 55 | Esophago-gastric junction cancer |
| 56 | Gastric cancer in elderly patients |
| 57 | AFP-producing gastric cancer |
| 58 | EBV-related gastric cancer |
| 59 | Gastrointestinal stromal tumor |
| 60 | Malignant lymphoma |
| 61 | Gastric neuroendocrine tumor |
| 62 | Fundic gland type gastric cancer |
| 63 | Guidelines |
| 64 | Clinical pathway |
| 65 | Postoperative surveillance |
| 66 | Long-term survival case after chemotherapy |
| 67 | Outcome |
| 68 | Prognostic factor |
| 69 | QOL assessment |
| 70 | Nutrition |
| 71 | Obesity |
| 72 | Japanese Classification of Gastric Carcinoma |
| 73 | Multidisciplinary treatment |
| 74 | Palliative therapy |
| 75 | Team approach |
| 76 | MDT conference |
| 77 | Medical cooperation |
| 78 | Oral care |
| 79 | Others |
Abstract Acceptance or Rejection
Please note that the decision on abstract acceptance/rejection and presentation style (oral, poster or video) is left to the sole discretion of the Congress President.
Abstract Submission
Language for abstract
English
Language for presentation
English
Language for presentation slides
English
The number of characters
Title: up to 100 characters (including spaces)
Abstract: up to 1600 characters (including spaces)
Travel Grants
We invite you to submit applications for travel grants with details as below. Please apply by selecting "Apply" at the time of abstract submission.
- Applicant's eligibility
- The applicant must be aged 40 or under at the time of abstract submission.
- The applicant must be working or training in a country other than Japan.
- The applicant may submit only one abstract.
- The presentation must be given and slides must be prepared in English.
- The travel grant of ¥100,000 will be awarded and participation will be free of charge. The applicant must arrange, however, transportation, accommodation, etc. on his/her own.
- The Congress President reserves the right of acceptance or rejection for all submitted presentations.
- It is the applicant's own responsibility to obtain the proper visa to enter Japan.
- Applicants will individually be notified of travel grant decisions by December 2017.
Conflict of Interest Disclosure
The author is required to report applicable COI (Conflict of Interest) by completing the "Conflict of Interest Disclosure" part in the Abstract Submission process.
 |
 |
Submission Page
Abstract Submission is now closed. Thank you for your submission.
Inquiries
Secretariat of 90th Annual Meeting of The Japanese Gastric Cancer Association.
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
Tel: +81-3-3508-1214 Fax: +81-3-3508-1302
E-mail: 90jgca[A]convention[D]co[D]jp( Please chainge [A] to @ [D] to . )
